ReviewEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024
Durability of transcatheter aortic valve implantation.
Review in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial.JAMA cardiology · 2026Trial
- Ten-Year Clinical Outcomes and Valve Durability After Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves.JACC. Asia · 2026Article
- Evolving Early Outcomes After Transcatheter Aortic Valve Replacement in Asian Patients: Temporal Trends From the OCEAN-TAVI Registry.Structural heart : the journal of the Heart Team · 2026Article
- A single-center study on prosthesis selection strategy in aortic valve replacement for patients aged 50-65 years.Journal of thoracic disease · 2026Article
- Current Trends and Future Challenges in Transcatheter Aortic Valve Implantation (TAVI): A Narrative Review.Journal of clinical medicine · 2026Review
- Taiwan Association of Thoracic and Cardiovascular Surgery (TATCS) Position Statement: Surgeon's Role in the Present Era of Isolated Severe Aortic Stenosis Patient Management.Acta Cardiologica Sinica · 2026Article
- Supra-Annular Versus Intra-Annular Devices for Transcatheter Aortic Valve-in-Valve Replacement: The PANDORA International Registry.Journal of the American Heart Association · 2026Article
- Redo TAVI: Improved Hemodynamics With a Supra-Annular Valve in a Small Annulus.JACC. Case reports · 2026Article
- Sex-based differences in 10-year outcomes and bioprosthetic durability after TAVR with self-expanding valve bio-prosthesis: insights from a multicenter cohort.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Comparing Clinical Outcomes of Patients With a Small Versus Large Annulus After Newer-Generation Balloon-Expandable Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2026Article
- Development of a Polymeric TAVR Device Tailored to Bicuspid Aortic Valve Patients Using In Silico Design Optimization and Evaluation.Annals of biomedical engineering · 2026Article
- Contemporary Life Expectancy Following Transfemoral Transcatheter Aortic Valve Replacement-Data From a National Registry Perspective.Structural heart : the journal of the Heart Team · 2026Article
- Surgical Explant of Degenerated Transcatheter Valves: A New Type of Threat?Interdisciplinary cardiovascular and thoracic surgery · 2026Review
- The Impact of Prosthesis-Patient Mismatch on Bioprosthetic Valve Durability After Transcatheter Aortic Valve Replacement.Structural heart : the journal of the Heart Team · 2026Article
- Association of bicuspid aortic valve stenosis with higher risk for hypoattenuated leaflet thickening following transcatheter aortic valve replacement.Cardiovascular diagnosis and therapy · 2025Article
- Management of Asymptomatic Severe Aortic Stenosis: Current Evidence and Future Directions.Journal of clinical medicine · 2025Review
- Transcatheter Aortic Valve Implantation in Young Patients: Challenges and Perspectives-A Narrative Review.Journal of clinical medicine · 2025Review
- Molecular Mechanisms of Cardiac Adaptation After Device Deployment.Journal of cardiovascular development and disease · 2025Review
- Four-year durability of the Myval balloon-expandable transcatheter aortic valve.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Long-term structural valve deterioration after TAVI: insights from the EORP ESC Valve Durability TAVI Registry.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve implantation (TAVI) is now utilised as a less invasive alternative to surgical aortic valve replacement (SAVR) across the whole spectrum of surgical risk. Long-term durability of the bioprosthetic valves has become a key goal of TAVI as this procedure is now considered for younger and lower-risk populations. The purpose of this article is to present a state-of-the-art overview on the definition, aetiology, risk factors, mechanisms, diagnosis, clinical impact, and management of bioprosthetic valve dysfunction (BVD) and failure (BVF) following TAVI with a comparative perspective versus SAVR. Structural valve deterioration (SVD) is the main factor limiting the durability of the bioprosthetic valves used for TAVI or SAVR, but non-structural BVD, such as prosthesis-patient mismatch and paravalvular regurgitation, as well as valve thrombosis or endocarditis may also lead to BVF. The incidence of BVF related to SVD or other causes is low (<5%) at midterm (5- to 8-year) follow-up and compares favourably with that of SAVR. The long-term follow-up data of randomised trials conducted with the first generations of transcatheter heart valves also suggest similar valve durability in TAVI versus SAVR at 10 years, but these trials suffer from major survivorship bias, and the long-term durability of TAVI will need to be confirmed by the analysis of the low-risk TAVI versus SAVR trials at 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.